News
GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. | Pfizer and BioNTech have settled an mRNA patent lawsuit originally brought by CureVac in the U.
BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
It's been a good week for BioNTech SE (NASDAQ:BNTX) shareholders, because the company has just released its latest quarterly results, and the shares gained 3.6% to US$111. It was a moderately negative ...
The intervention under investigation is GEN1056, a biological treatment administered via intravenous infusion. Its primary purpose is to evaluate safety and antitumor activity, with the ultimate goal ...
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
Stocktwits on MSN3d
BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline PushBioNTech is back in Wall Street’s spotlight after posting better-than-expected second-quarter results and doubling down on ...
BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback